心源性与非心源性卒中血管内再通后动脉内替奈普酶结局
POST-TNK试验预设二次分析,将540例急性缺血性卒中患者按病因分为心源性栓塞(CE,n=272)与非CE(n=268)两组,评估血管内治疗达到近完全至完全再灌注后辅助动脉内替奈普酶(TNK)的安全性与有效性。结果显示,CE组动脉内TNK与90天无残疾概率显著升高相关(校正OR 1.80,95%CI 1.02-3.16,P=0.04),且未增加死亡或颅内出血风险;非CE组未见功能获益。
要点
- CE患者EVT近完全再灌注后辅助动脉内TNK与90天无残疾率升高相关
- CE组动脉内TNK未增加90天死亡、48小时内sICH或任何ICH风险
- 非CE患者中动脉内TNK未显示功能结局改善
核心结论
- 心源性栓塞所致AIS患者EVT达到2c-3再灌注后,辅助动脉内TNK与90天无残疾可能性更高相关,且不增加死亡或ICH风险。
- 非心源性栓塞AIS患者中未观察到动脉内TNK的功能获益。
研究设计与样本
- POST-TNK随机、开放标签、盲法结局评估试验的预设二次分析,共纳入540例患者。
- 按卒中病因分为心源性栓塞组(n=272)与非心源性栓塞组(n=268)。
主要发现
- CE组272例中,对照组137例、动脉内TNK组135例,中位年龄73岁(IQR 66-78),男性47.1%。
- CE组动脉内TNK与90天无残疾(mRS 0-1)显著更高相关:校正OR 1.80(95%CI 1.02-3.16,P=0.04);IPTW校正OR 1.58(95%CI 1.12-2.22,P=0.01)。
- CE组两组间90天死亡率、48小时内sICH及48小时内任何ICH均无显著差异。
- 非CE组动脉内TNK与功能结局改善无关联。
关键数值与推荐
- 近完全至完全再灌注定义为eTICI评分2c-3。
- 主要结局为90天无残疾,定义为mRS评分0-1。
- 安全性结局包括90天死亡率、48小时内sICH及48小时内任何ICH。
临床怎么用
- 对心源性栓塞所致AIS且EVT后达到eTICI 2c-3再灌注的患者,可考虑辅助动脉内TNK以改善90天功能结局。
- 非心源性栓塞患者中,动脉内TNK未见功能获益,决策时应结合病因个体化评估。
局限性
- 为POST-TNK试验的二次分析,按病因分组的亚组结果需谨慎解读。
- 原文摘要未报告非CE组的具体效应量及置信区间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to evaluate the safety and effectiveness of adjunctive intra-arterial tenecteplase (TNK) in patients with acute ischemic stroke (AIS) due to cardioembolism (CE) and non-CE who achieved near-complete to complete reperfusion (defined as an expanded thrombolysis in cerebral infarction score of 2c-3) following endovascular treatment (EVT). METHODS: This prespecified secondary analysis of the POST-TNK randomized, open-label, blinded outcome assessment trial categorized 540 patients by stroke etiology into CE (n = 272) and non-CE (n = 268) subgroups. The primary outcome was freedom from disability at 90 days, defined as a modified Rankin Scale score of 0 to 1. Safety outcomes included 90-day mortality, symptomatic intracranial hemorrhage (sICH) within 48 hours, and any intracranial hemorrhage (ICH) within 48 hours. RESULTS: Among 272 patients with CE (median age, 73 years [interquartile range, 66-78]; 47.1% male), 137 were assigned to the control group and 135 to the intra-arterial TNK group. Compared with the control group, intra-arterial TNK was associated with significantly higher odds of freedom from disability at 90 days (adjusted odds ratio, 1.80; 95% confidence interval [CI], 1.02-3.16; p = 0.04; inverse probability of treatment weighting adjusted odds ratio, 1.58; 95% CI, 1.12-2.22; p = 0.01). No significant differences were observed in 90-day mortality, sICH, or any ICH within 48 hours between groups. Conversely, intra-arterial TNK was not associated with improved functional outcomes in patients with AIS due to non-CE. INTERPRETATION: In patients with AIS due to CE who achieved near-complete to complete reperfusion after EVT, adjunctive intra-arterial TNK was associated with a higher likelihood of freedom from disability at 90 days, without increasing the risk of mortality or ICH. However, this benefit was not observed in AIS patients due to non-CE. ANN NEUROL 2026;100:841-849.
引用
- Chai M, Zhang Q, Zhao X, et al. Outcomes of Intra-Arterial Tenecteplase after Endovascular Reperfusion for Acute Ischemic Stroke Due to Cardioembolism and Non-Cardioembolism: A Secondary Analysis of the POST-TNK Trial. Ann Neurol. 2026. PMID: 42565455. doi:10.1002/ana.78304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。